Colorectal Cancer Policy Will Not Limit Current Off-Label Coverage, CMS Says
Executive Summary
The Centers for Medicare & Medicaid Services' national coverage determination for four colorectal cancer therapies will not limit coverage of other off-label indications, the agency said
You may also be interested in...
Medicare To Use Evidence Development For Off-Label Drug Use? CMS Guidance Unclear
CMS’ guidance on its “coverage with evidence development” policy for Medicare Part B does not elaborate on the scope of its application to off label drug use, only stating the agency could apply CED to drugs that have received FDA approval for at least one indication.
A Closer Look: Colorectal Cancer National Coverage Decision After One Year
Nearly a year after CMS finalized a contentious national coverage decision (NCD) on certain off-label uses of colorectal cancer drugs, five out of nine eligible clinical trials have yet to open for patient enrollment, according to the National Cancer Institute (NCI)
A Closer Look: Colorectal Cancer National Coverage Decision After One Year
Nearly a year after CMS finalized a contentious national coverage decision (NCD) on certain off-label uses of colorectal cancer drugs, five out of nine eligible clinical trials have yet to open for patient enrollment, according to the National Cancer Institute (NCI)